Amgen Eschews Some Of Its BiTEs, But Otezla Spurs Growth
Pipeline Changes Planned As Data Evolved
Executive Summary
Without Otezla’s $2.2bn in 2020 sales, Amgen’s full-year revenue would have been slightly lower than in 2019, which is why all eyes are on the company’s R&D programs and near-term approvals.
You may also be interested in...
Amgen CEO Shines Light On Opportunities For Accelerated Drug Pathways
Amgen CEO Robert Bradway spotlights opportunities to up the tempo of drug discovery and development, drawing from the success of COVID-19 vaccines, and touches on the company's breakthrough treatment Lumakras and efforts in gastric cancer.
Amgen Is Still ‘A Biotech At Heart’
Head of Amgen’s inflammation business, Kave Niksefat, gives insight into how the 40-year-old biotech maintains its culture of innovation and avoids falling into the “trap” of bureaucracy.
Novartis's Targeted Radioligand Improves OS And PFS In Prostate Cancer
Novartis’s PSMA-targeted radioligand has improved overall survival and progression-free survival in top-line results from the Phase III VISION study in prostate cancer, cementing the company's pioneering role in the therapeutic area.